Researchers at the ICR identified the BRCA2 inherited genetic mutation in the 1990s. Men with this mutation have a higher risk of prostate cancer and women have a very high risk of developing breast and ovarian cancer. This was the second such BRCA genetic mutation identified.
Researchers at the ICR’s Breakthrough Breast Cancer Centre discovered that a new class of drugs called PARP inhibitors attacks breast, ovarian and prostate cancer tumours carrying BRCA1 and 2 genetic mutations.
Professor Johann de Bono and his team are now leading research trials testing the drug in prostate, breast and ovarian cancer patients.